ciclesonide + indacaterol

The ciclesonide + indacaterol combination is a novel pharmaceutical formulation that combines two distinct medications for respiratory conditions. This combination pairs ciclesonide, a non-halogenated corticosteroid, with indacaterol, a long-acting beta-2 adrenergic receptor agonist (LABA). ## Drug Information Ciclesonide is a prodrug that is enzymatically hydrolyzed in the lungs to form its active metabolite, desisobutyryl-ciclesonide, which exhibits pronounced anti-inflammatory activity[5]. It works by inhibiting leukocyte infiltration at inflammation sites, interfering with inflammatory response mediators, and suppressing humoral immune responses[2]. Indacaterol is a long-acting beta-2 adrenergic receptor agonist with a 24-hour duration of action that allows for once-daily dosing[8]. It stimulates adrenergic beta-2 receptors in airway smooth muscle, causing relaxation and increasing airway diameter[1]. Indacaterol has a rapid onset of action (within 5 minutes) due to its high intrinsic efficacy[1][6]. ## Therapeutic Applications The combination of ciclesonide and indacaterol provides a complementary approach to treating respiratory conditions: - Ciclesonide manages chronic inflammation associated with asthma and COPD - Indacaterol improves abnormalities in bronchial smooth muscle[5] This combination offers the convenience of once-daily administration for patients with asthma and COPD, while simultaneously reducing dosage frequency[5]. The patent information indicates that the combination exhibits synergistic activity, with ciclesonide helping to increase indacaterol's activity while indacaterol improves ciclesonide's efficacy[5]. ## Dosage Information According to the patent information, the combination may contain: - Indacaterol: 20 mcg to 1200 mcg - Ciclesonide: 20 mcg to 800 mcg[5] The pharmaceutical composition comprises indacaterol and ciclesonide with one or more pharmaceutically acceptable excipients[5]. ## Mechanism of Action The combination works through dual mechanisms: 1. **Ciclesonide**: Acts as an anti-inflammatory agent by inhibiting phospholipase A2 inhibitory proteins (lipocortins), which control the biosynthesis of inflammatory mediators like prostaglandins and leukotrienes[2]. 2. **Indacaterol**: Functions as a bronchodilator by stimulating beta-2 adrenergic receptors in airway smooth muscle, increasing cyclic AMP levels and causing muscle relaxation[1][6]. This dual approach addresses both the inflammatory and bronchoconstrictive components of respiratory diseases like asthma and COPD.